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Introduction: Mesenchymal stem cell-conditioned medium (MSC-CM) has been shown to have protective effects
against various cellular-injury models. This mechanism of protection, however, has yet to be elucidated. Recently,
exosomes were identified as the active component in MSC-CM. The aim of this study is to investigate the effect
of MSC-derived exosomes in an established carbon tetrachloride (CCl4)-induced liver injury mouse model. This
potential effect is then validated by using in vitro xenobiotic-induced liver-injury assays: (1) acetaminophen
(APAP)- and (2) hydrogen peroxide (H2O2)-induced liver injury.
Methods: The exosomes were introduced concurrent with CCl4 into a mouse model through different routes of
administration. Biochemical analysis was performed based on the blood and liver tissues. Subsequently the
exosomes were treated in APAP and H2O2-toxicants with in vitro models. Cell viability was measured, and
biomarkers indicative of regenerative and oxidative biochemical responses were determined to probe the
mechanism of any hepatoprotective activity observed.
Results: In contrast to mice treated with phosphate-buffered saline, CCl4 injury in mice was attenuated by
concurrent-treatment exosomes, and characterized by an increase in hepatocyte proliferation, as demonstrated with
proliferating cell nuclear antigen (PCNA) elevation. Significantly higher cell viability was demonstrated in the
exosomes-treated group compared with the non-exosome-treated group in both injury models. The higher survival
rate was associated with upregulation of the priming-phase genes during liver regeneration, which subsequently
led to higher expression of proliferation proteins (PCNA and cyclin D1) in the exosomes-treated group. Exosomes
also inhibited the APAP- and H2O2-induced hepatocytes apoptosis through upregulation of Bcl-xL protein expression.
However, exosomes do not mitigate hepatocyte injury via modulation of oxidative stress.
Conclusions: In summary, these results suggest that MSC-derived exosomes can elicit hepatoprotective effects against
toxicants-induced injury, mainly through activation of proliferative and regenerative responses.Introduction
Liver is one of the few organs in the body that possesses
an immense capacity to regenerate through the replica-
tion of mature functioning liver cells [1]. This protective
response is of clinical significance particularly during
liver injury. However, when the injury progresses into a
state of functional impairment, it can overwhelm or even
inhibit the intrinsic regenerative potential, leading to se-
vere consequences that include acute liver failure or* Correspondence: phahohk@nus.edu.sg
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unless otherwise stated.death [2]. Today, xenobiotic (drugs)-induced liver injury
accounts for more than 50% of acute liver failure in the
United States and has become a major clinical problem
[3]. To overcome this issue, we must explore potential
therapeutic agents that can prevent further damage to
the injured liver cells. Alternatively, agents that can
stimulate remnant liver cells to regenerate could also
help to restore liver function in a timely manner and to
avert longer-term sequelae.
Mesenchymal stem cell (MSC)-based therapy has been
extensively investigated in the area of regenerative medi-
cine for different organs (heart, kidney, lung, and liver) be-
cause of its ability to differentiate and transdifferentiate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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into adipocytes and chondrocytes) [4], stimulate regener-
ation, and repair damaged tissue/organs [5]. However, re-
cent reports showed that the bioactive soluble factors
found in MSC-conditioned medium (MSC-CM) can
stimulate host responses for repair and also reduce the
liver-injury level in several different injury models, even
without MSC [6-8]. As compared to cell-based therapies,
MSC-CM (non-cell-based) therapies are generally pre-
ferred because they are less likely to trigger immune re-
sponse, rendering them safer to use. In addition, they are
more amenable to reformulation to support different
routes of administration.
Recently, proteomic and computational analysis on the
MSC-CM revealed that the secretome in this condition
medium (CM) could exert potential modulating effects
on tissue repair and regeneration in heart, kidney, and
liver [9]. More important, it was demonstrated that the
observed cardiac-function preservation was derived from
exosomes, a fraction of particle size with 55–100 nm, bi-
lipid membrane secreted microvesicle purified from the
MSC-CM [10]. However, it remains to be determined
if these size-purified exosomes are able to enrich the
hepatoregenerative effect found previously in the condi-
tioned medium, and whether they are efficacious in
overcoming liver injury. Furthermore, their ability to
respond to different mechanisms of liver injury has not
been investigated.
Therefore, this work set out first to explore the poten-
tial therapeutic effect in an established CCl4-induced
acute liver-injury mouse model followed by characteriz-
ing this potential effect by using liver cell-culture models
of well-defined xenobiotic-induced liver injury.
Materials and methods
Materials and reagents
Dexamethasone, nicotinamide, gentamicin, HEPES, NaCl,
EDTA, glycerine, Triton-X, sodium fluoride, sodium
orthovanadate, phenylmethanesulfonyl fluoride (PMSF),
aprotinin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT), acetaminophen (APAP), hydro-
gen peroxide (H2O2), carbon tetrachloride (CCl4), and
olive oil were obtained from Sigma Chemical (St. Louis,
MO, USA). Dulbecco modified Eagle medium/Ham F12
(DMEM/F12), and Superscript III First-strand Synthesis
System are products of Invitrogen (Carlsbad, CA, USA). In-
sulin, transferrin, and selenium (ITS) is from BD (Franklin
Lakes, NJ, USA). Dimethylsulfoxide (DMSO) was obtained
from Merck (Darmstadt, Germany). SYBR Green PCR
master mix was obtained from Applied Biosystems
(Warrington, UK). RNeasy mini kit is a product of Qiagen
(Hilden, Germany). Phosphate-buffered saline (PBS) and
all primers were synthesized by 1st BASE Oligos (Singapore).
Primary antibodies were purchased from the followingcompanies: phospho (Tyr705)-STAT 3, proliferating cell
nuclear antigen (PCNA), NF-κB p65, cyclin D and cyclin
E, Cell Signaling Technology (Danvers, MA, USA); hep-
atocyte growth factor (HGF), Abcam (Cambridge, UK).
MSC-derived exosomes was prepared and purified as de-
scribed previously [10].
Animals and diets
Six-week-old male C57BL/6 mice (21 to 27 g) were sup-
plied by the Lab Animals Centre, Singapore. Animals
were housed in animal-holding units in National Univer-
sity of Singapore (NUS) at a constant temperature in a
12/12-hour light/dark cycle. All animal procedures were
carried out according to a protocol approved by the Na-
tional University of Singapore Institutional Animal Care
& Use Committee, Protocol number 123/09. The mice
were acclimatized for 2 weeks before use; the mice were
8 weeks of age at the time of experiments. Before the ex-
periment, mice were allowed free access to food and
water.
Preparation of MSC-derived exosomes
The collection of fetal tissue was carried out under a KK
Women’s and Children’s Hospital (KKH) IRB-approved
protocol (EC200804062) [11]. Only patients who had
already consented to Termination of Pregnancy (TOP)
in theKKH Outpatient Clinic were recruited. Recruit-
ment was carried out in strict adherence to KKH IRB
regulations to ensure the patient’s rights and privacy,
and to provide confidential counseling for the patient’s
fully informed consent to voluntary donation. The pa-
tients gave their informed consent for fetal tissue to be
collected and used in this study. The hESC-derived
HuES9.E1 MSCs were used for the production of MSC
secretion in the form of CM, as described [10].
To harvest MSC secretion, 80% of the confluent
HuES9. E1 cultures were washed with PBS, transferred
to a chemically defined, serum-free culture medium for
an overnight incubation, washed with PBS, and cul-
tured in fresh, chemically defined, serum-free culture
medium for 3 days. The CM was collected, clarified by
centrifugation, and was concentrated 50× by tangential
flow filtration (TFF) by using a membrane with a 100-kDa
MWCO (Sartorius, Goettingen, Germany). CM was
fractionated by high-performance liquid chromatog-
raphy (HPLC) (TSK Guard column SWXL, 6 × 40 mm
and TSK gel G4000 SWXL, 7.8 × 300 mm, Tosoh Corp.,
Tokyo, Japan).
Exosomes were collected from the first peak of the
elution and concentrated by using 100 kDa MWCO fil-
ter (Sartorius). The identity of the exosomes used in this
study had been previously characterized by Lai et al.
[10]. Exosomes were filtered with a 0.22-μm filter and
stored in a -20°C freezer until use.
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All mice received a single dose of CCl4 (3% vol/vol in
olive oil) at 0.05 ml/kg body weight by intraperitoneal
injection (i.p.). 0.4 μg (100 μl) exosomes or 100 μl PBS
were administered through intrasplenic injection (i.s.)
for the treatment group and the vehicle-control group,
respectively. All mice were killed 24 hours after CCl4,
blood, and livers were collected. The aspartate amino-
transferase (AST) and alanine aminotransferase (ALT)
activities in the serum were analyzed by using Cobas
4000 analyzer series (Roche, Basel, Switzerland).
Cell lines and culture conditions
Three different types of hepatocytes were used in the
study of cell viability. TAMH, an immortalized mouse
hepatocyte line derived from transgenic MT42 male
mice overexpressing TGF-α [12], was used as a metabol-
ically competent liver cell line that reproduced features
of cytotoxicity to support this investigation, whereas
THLE-2 is an immortalized primary human hepatocyte
that expresses phenotypic characteristics of normal adult
liver epithelial cells [13].
In contrast with the normal cell line, we also investigated
the effect of exosomes in HuH-7, a well-differentiated hu-
man hepatocarcinoma cell line. This comparison will help
to strengthen the evidence of therapeutic effect of exosomes
against different liver-injury model in various liver cell types.
Immortalized murine transforming growth factor alpha
(TGF-α) transgenic hepatocyte (TAMH) cells [14] (ob-
tained as a kind gift from Prof Nelson Fausto, University
of Washington, Seattle, WA, USA), were maintained in
DMEM/F12 supplemented with 5 mg/ml insulin, 5 mg/ml
transferrin, 5 ng/ml selenium, 100 nM dexamethasone, 10
mM nicotinamide, and 0.01% (vol/vol) gentamicin. HuH-7
obtained from HSRRB (Tokyo, Japan), a human hepato-
carcinoma cell line was grown in Dulbecco modified Eagle
medium (DMEM) (Sigma) supplemented with 10% fetal
bovine serum (FBS) (Hyclone). THLE-2 obtained from
ATCC (Manassas, VA, USA), a human normal liver cell,
was cultured in LHC-9 medium supplemented with 10%
FBS (Hyclone). The flasks used were pre-coated with a
mixture of 0.01 mg/ml fibronectin, 0.03 mg/ml bovine col-
lagen type I, and 0.1 mg/ml bovine serum albumin (BSA)
dissolved in LHC-9 basal medium.
All cells were maintained at 37°C in humidified 95%
air and 5% CO2 atmosphere, passaged and seeded at
80% to 90% confluency.
In vitro cell-viability assay
With 96-well plates, TAMH cells were seeded at a density
of 6 × 103 cells/well in 200 μl DMEM/F12 medium,
whereas THLE-2 cells were seeded at a density of 1 × 104
cells/well in 200 μl LHC-9 medium overnight. HuH-7
cells were seeded at a density of 5 × 103 cells/well for 72-hour treatment, and 7.5 × 103 cells/well for 24-hour treat-
ment in 200 μl DMEM medium overnight. TAMH, HuH-7,
and THLE-2 cells were treated with various concentra-
tions of exosomes in their respective culturing medium
for 24 or 72 hours. Cell-viability assays were performed
after the respective incubation time to determine the cyto-
toxicity of exosomes. In TAMH cells, 2 mM APAP or 350
μM H2O2 was treated in the TAMH cells concurrent with
0.05 μg/ml or 0.1 μg/ml of exosomes for 24 hours before
performing the cell-viability test. HuH-7 and THLE-2 cells
were treated with 5 mM and 3.5 mM APAP, respectively,
with 0.05 μg/ml or 0.1 μg/ml of exosomes for 72 hours be-
fore performing the cell-viability test.
PBS was used as background for exosomes treated in the
control groups. After incubation of toxicants with different
concentrations of exosomes, the cell viability was evaluated
with MTT assay. Then 20 ml of 5 mg/ml MTT was dis-
solved in PBS. After the incubation period, the media was
aspirated, and the formazan crystals in cells were dissolved
in 200 μl of DMSO and 25 μl of Sorenson buffer [15]. The
absorbance was read at 570 nm by using a Tecan microti-
ter plate reader. Cell-viability percentage was expressed as
a ratio of cells exposed to different concentrations of toxi-
cants with those of vehicle controls.
Reverse transcription and quantitative real-time
polymerase chain reaction
In a six-well plate, TAMH cells were seeded at a density of
0.5 × 106 cells/well and treated with 2 mM APAP or 350 μM
H2O2 concurrent with 0.05 mg/ml or 0.1 mg/ml of exo-
somes for 24 hours. All cells were harvested for total cell
RNA extraction by using RNeasy columns (Qiagen, Valencia,
CA, USA). The quality and quantity of total RNA was deter-
mined with NanoDrop (Thermo, Wilmington, DE, USA),
ensuring that RNAs with OD 260/280 > 1.80 were used.
First-strand cDNA was synthesized from 1 μg total RNA by
using Superscript First-Strand Synthesis System, according to
the protocols of the manufacturer. qRT-PCR was performed
by using BioRad CFX96 real-time PCR system with SYBR
Green master mix and primers, as shown in Table 1. The
thermal-cycling condition comprised an initial denaturation
at 95°C (10 minutes), followed by 40 cycles at 95°C (15 sec-
onds) and 60°C (60 seconds). Melting curves were generated
at the end of 40 cycles to verify the purity of the PCR prod-
uct. Data were obtained as average Ct values, and normalized
against the geometric mean of GAPDH endogenous controls
as Ct. Transcript differences between the exosomes-treated
group and the nontreated group were measured as fold
changes by using the comparative Ct method. Statistics were
performed on Ct by using REST software (Qiagen).
Western blots
Mouse liver tissue was homogenized by using glass dounce
homogenizer. Proteins were lysated with 800 μl of lysis
Table 1 Sequences of primers used in real-time PCR reaction
Gene Forward primer (5ʹ- > 3ʹ) Reverse primer (5ʹ- > 3ʹ)
In vitro hepatocytes (TAMH cells)/In vivo liver (mouse)
TNF-α ATG AGC ACA GAA AGC ATG ATC TAC AGG CTT GTA ACT CGA ATT
IL-6 AGT TGC CTT CTT GGG ACT GA TCC ACG ATT TCC CAG AGA AC
iNOS CAC CTT GGA GTT CAC CCA GT ACC ACT CGT ACT TGG GAT GC
COX-2 CTC CCT GAA GCC GTA CAC AT GCT CGG CTT CCAA GTA TTG AG
MIP-2 AAG TTT GCC TTG ACC CTG AA AGG CAC ATC AGG TAC GAT CC
HO-1 CAG GTG ATG CTG ACA GAG GA ATG GCA TAA ATT CCC ACT GC
Gpx4 CCG GCT ACA ACG TCA AGT TT CGG CAG GTC CTT CTC TAT CA
Gsr ACC ACG AGG AAG ACG AAA TG GGT GAC CAG CTC CTC TGA AG
MnSOD GGC CAA GGG AGA TGT TAC AA CCT TGG ACT CCC ACA GAC AT
GAPDH GGC ATT GCT CTC AAT GGAC AA CCG AGGT TGG GAT AGG GCC
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mM EDTA, 10% glycerine, 1% triton-X, 0.5 M sodium
fluoride, 100 mM sodium orthovanadate, 100 mM PMSF,
and 20 mg/ml aprotinin. TAMH cells were seeded at 2 ×
106 in a 10-cm dish with DMEM/F12 medium overnight.
The medium was changed to DMEM/F12 low glucose and
cultured for 2 days. Cells were then treated with respective
concentrations of APAP or H2O2 and exosomes for 24
hours. All cells were harvested for Western blot analysis.
Cell pellets were lysed with 100 μl of RIPA lysis buffer
containing 50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5%
sodium deoxycholate, 1% NP-40, 0.5 M sodium fluoride,
100 mM sodium orthovanadate, 100 mM PMSF, and
20 mg/ml aprotinin. The 40 mg total protein per mouse
sample and 10 μg per cell sample were resolved in 10%
SDS-PAGE and immobilized on PVDF membrane. The
membranes were blocked in 5% milk for 1 hour and incu-
bated in respective primary antibodies overnight (pSTAT3,
1:1,000; NF-κB, 1:2,000; Bcl-xL 1:1,000; PCNA, 1:10,000;
and cyclin D1, 1:1,000), followed by respective secondary
antibody (1:10,000) incubation for 1 hour. All membranes
were visualized by using chemiluminescence substrate
(Pierce Biotechnology, Rockford, IL, USA). The band in-
tensities were normalized against actin and were quanti-
fied by using ImageJ software.
Statistical analysis
Data were expressed as means ± standard error of means
(SEM) and analyzed by using Student two-tailed t test.
Statistical significance of the difference was accepted at
P-values of less than 0.05.
Results
Exosomes reduced liver-injury level in ALT and AST after
CCl4 treatment in vivo
A preliminary experiment revealed that serum AST and
ALT gradually increased and peaked at 24 hours after a
single dose of CCl4 (data not shown). Thus, AST andALT were measured at 24 hours after respective treat-
ments. Mice receiving 0.05 ml/kg CCl4 demonstrated sig-
nificant increases in AST and ALT within 24 hours of
dosing. In mice treated with CCl4 and exosomes, the in-
crease of AST and ALT after 24 hours was significantly
less than the PBS-treatment group (Figure 1A). Histologi-
cally, the hematoxylin and eosin (H&E) staining of liver
tissues for the CCl4 group showed moderate hepatic ne-
crosis, whereas minimal necrotic cells were observed in
the exosomes treatment group (Figure 1B).
Exosomes induced hepatocyte-regenerative genes
expression in liver tissue after CCl4-induced injury
To investigate the regenerative effect of exosomes, few
of the transcription factors and growth factors expres-
sion involved in different stages of the cell cycle were ex-
amined by using immunoblot assays on the liver tissue.
As can be seen from Figure 2A, the exosomes treatment
group showed significant upregulation of the hepatic
gene expressions of NF-κB, cyclin D1, and cyclin E in
contrast with the untreated. No significant upregulation
was observed for HGF and p-STAT3 gene expression.
The activation of proliferation was also demonstrated by
the higher number of PCNA+-stained cells in the exo-
somes treatment group (Figure 2C) as compared with
the PBS-treatment group (Figure 2B).
Exosomes exerted no intrinsic cytotoxicity while
demonstrating increased cell viability in TAMH, THLE-2, and
Huh-7 hepatocytes after APAP- or H2O2-induced injuries
In vitro models were subsequently designed to validate
the in vivo findings of exosomal protection and to gain
further insights into its response toward different mech-
anisms of toxicity; APAP represents the liver-injury
model caused by both covalent modification of protein
targets and oxidative stress-mediated injury pathways
[16], whereas H2O2 represents only the oxidative stress-














































Figure 1 Effect of exosomes on biochemical parameters and hepatocyte injury after CCl4 treatment in vivo. Serum (A) aspartate
aminotransferase (AST) and (B) alanine aminotransferase (ALT) levels were measured after 24-hour dosing of CCl4 with or without exosomes
administration (n = 6 per group; *P < 0.05 versus of CCl4 control for both AST and ALT). Standard hematoxylin and eosin (H&E) staining for liver
tissue harvested after 24 hours of (C) CCl4 administration and (D) CCl4 with exosomes treatment. Obvious hepatic necrosis appeared in the
section from a CCl4-treated animal. Original magnification × 80; scale bar, 100 μm.
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jected to these xenobiotic-induced injuries. The exosomes
concentration used in this study was 0.1 μg/ml. This
concentration was chosen as it had demonstrated cardi-
oprotection in a previous study [10]. Further in our
current evaluation, this concentration did not display
any cytotoxicity across the three cell lines (Figure 3A,D,
G). Cytoprotection against APAP- and H2O2-induced
liver injury in TAMH cells was clearly demonstrated
(Figure 3B,C). The same concentration of exosomes
seemed to demonstrate better protection against APAP
injury as compared with the H2O2-injury model. When
cross-referenced and confirmed with THLE-2 and HuH-
7, comparable results were observed. Treatment of 0.1
μg/ml exosomes demonstrated significantly higher cell
viability in both toxicant-induced liver-injury models by
using THLE-2 (Figure 3D-F) and HuH-7 when com-
pared with untreated cells (Figure 3G-I).
Exosomes regulated hepatocytes proliferation through
inducing quiescent hepatocytes (G0) to re-enter the cell cycle
(G1) at the priming phase after APAP- or H2O2-induced injury
By determining the modulation of early priming cytokines
expression, an exosomal mechanism of cytoprotection
could be elucidated. Hence, cell growth was first arrested
by culturing in low-glucose DMEM/F12 medium for 2days. Then, treatment with APAP or H2O2 was introduced,
either with or without MSC exosomes. Finally, gene-
expression levels of the priming factors were measured
after 24 hours of these treatments. As shown in Figure 4A
and B, 0.1 μg/ml of exosomes-treated group was observed
to have elevated mRNA expressions of tumor necrosis fac-
tor alpha (TNF-α), interleukin 6 (IL-6), inducible nitric
oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and
macrophage inflammatory protein 2 (MIP-2), as compared
with the untreated group.
In the APAP-injury model, MIP-2 demonstrated the
highest elevation with 3.7-fold, followed by 2.4-fold in
COX-2 and twofold in iNOS. The elevation trend differed
slightly in the H2O2-injury model, whereby the same
amount of exosomes was found to increase iNOS expres-
sion the most significantly, by approximately 2.9-fold,
followed by twofold increase in all three MIP-2, COX-2,
and IL-6 genes compared with the non-exosomes-treated
group (Figure 4B).
Exosomes induced transcription factors expression during
the G1 phase of cell cycle after APAP- or H2O2-induced injury
Based on the observed elevation of TNF-α and IL-6 with
exosomal treatment, the downstream effect of NF-κB
and STAT3 transcription factors activation in the G1










































Figure 2 Effect of exosomes on hepatocyte proliferation after CCl4-induced injury in mice. (A) Expression of cyclin E, HGF, pMet, NF-κB
p65, cyclin D1, and phosphorylated STAT3 was determined by immunoblotting after 24 hours of CCl4 administration with or without exosomes
(n = 6 per group (three per group were shown); *P < 0.05 versus CCl4 control). The relative densities of all the proteins bands were normalized
to actin in the same samples. Livers were processed for immunohistochemistry on PCNA to quantify hepatocyte proliferation after 24 hours of
(B) CCl4 administration and (C) CCl4 with exosomes treatment. Original magnification × 200; scale bar, 100 μm.
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liver regeneration [17]. The activation of these factors
was investigated by immunoblotting of NF-κB (p65 and
p50) and phospho-STAT3 (TYR705) after treatmentof exosomes in both xenobiotic-induced hepatocyte-
injury models. Without exosomes treatment, APAP- and
H2O2-treated cells exhibited low basal levels of NF-κB and














































































































































































Figure 3 Effect of exosomes in cell viability after APAP- and H2O2-induced injury. Experiments were performed in TAMH (A-C), THLE-2 (D-F),
and Huh-7 (G-I) hepatocytes. (A, D, G) Cytotoxicity of exosomes at different concentrations in respective cell lines. 0.05 μg/ml and 0.1 μg/ml of
exosomes were added to respective concentration of APAP (B, E, H) and H2O2 (C, F, I), and MTT were performed 24 or 72 hours later. Cell viability was
normalized against vehicle control group and expressed in percentage (n= 6 per group; *P< 0.05 versus APAP or H2O2 non-exosomes-treatment group.
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p50 and p65) and phospho-STAT3 activities were re-
stored to the normal expression levels in APAP-induced
injury (Figure 5, lanes 3 and 4). Interestingly, higher
levels of induction of the two proteins were more prom-
inent in the H2O2-treated cells (Figure 3, lanes 6 and 7).Exosomes upregulated the expression of cell-proliferation
markers (at G1 and S phase) after APAP- or H2O2-induced
injury
After the observed restoration of NF-κB and STAT3
signaling with exosomal treatment, we pursued the search


























































































Figure 4 Effect of exosomes in hepatoregenerative-expression genes on APAP- and H2O2-induced injury in hepatocytes. Expression of
regenerative-response genes after 24 hours of exosomes in (A) APAP and (B) H2O2 treatment was determined by quantitative real-time PCR
and normalized against GAPDH expression of the same sample and presented as fold-increase over the controls. Bars represent means ± SEM.
*P < 0.05 versus APAP or H2O2 nonexosomes treatment group.
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expression of cyclin D1 and PCNA in a dose-dependent
manner during APAP and H2O2 injury (Figure 6). This
finding is consistent with our earlier results, which dem-
onstrated that MSC-derived exosomes promoted hepato-
cyte regeneration and proliferation during acute injury.
Exosomes protected hepatocytes from apoptosis by
decreasing caspase 3/7 level while upregulating
antiapoptotic gene Bcl-xL
Besides being a mitogenic transducer, STAT3 is also indica-
tive of early response toward promotion of antiapoptotic
activity. STAT3 could also suppress Fas-mediated liver in-
jury either by a redox-dependent mechanism through ex-
pressing antiapoptotic genes such as Bcl-xL, Bcl-2 [18], or
by a redox-independent mechanism through expressing
Ref-1 [19] or anti-oxidative gene, manganese superoxide
dismutase (MnSOD) [20]. To further determine if the anti-apoptotic effect was due to the upregulation of p-STAT3,
caspase 3/7 activities were measured in this study. Both
toxicant-only treatments resulted in significant increment
of active caspase 3 and reduction of antiapoptotic gene,
Bcl-xL, as compared with the control (Figure 7A,B). Similar
to the favorable outcomes in cell viability, in APAP-injury
model, exosomes treatment significantly suppressed the ac-
tivity of caspase 3. This suppression was not observed in the
H2O2-injury model. As for Bcl-xL, treatment of exosomes
seemed to reverse the suppression observed in toxicant-only
treatment. With higher exosomes concentrations, further in-
crease in expression was demonstrated in both APAP- and
H2O2- induced injury models (Figure 7B, lanes 4 and 7).
Exosomes did not regulate the antiapoptotic effect
through antioxidative genes
Further to assess the antiapoptotic effect of exosomes medi-
ated through the antioxidative pathway, mRNA expression
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Figure 5 Effect of exosomes in G1 phase of the cell cycle after APAP- or H2O2-induced injury in hepatocytes. Expression of NF-κB (p65
and p50) and phosphorylated STAT3 was determined by immunoblotting after 24-hour treatment in APAP- or H2O2-injury models. The relative
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Figure 6 Effect of exosomes in cell proliferation after APAP- or H2O2-induced injury in hepatocytes. Expression of cyclin D1 and PCNA
was determined by immunoblotting after 24-hour treatment in the APAP- or H2O2-injury model. The relative densities of cyclin D1 and PCNA
bands were normalized to actin in the same samples.
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Figure 7 Effect of exosomes on antiapoptosis in APAP- or H2O2-induced injury in hepatocytes. (A) Caspase 3/7 was measured after
24-hour treatment of exosomes in APAP or H2O2 injury. (B) Expression of Bcl-xL was determined by immunoblotting after 24-hour treatment
in the APAP- or H2O2-injury model. *P < 0.05 versus APAP or H2O2 non-exosomes treatment group. The relative densities of Bcl-xL bands
were normalized to actin in the same samples.
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volved in the oxidative pathway namely heme oxygenase-1
(HO-1), glutathione peroxidase 4 (Gpx4), glutathione re-
ductase (GSR), and MnSOD were measured. In both in-
jury models, only HO-1 mRNA expression was highly
induced at the 24-hour time point of each toxicant treat-
ment, whereas Gpx4, GSR, and MnSOD genes remainedrelatively unchanged, as compared with control. However,
no significant difference appeared between the exosomes-
and non-exosomes-treated groups (Figure 8A,B).
Discussion
We hypothesized that the size-purified subset of exosomes




































































Figure 8 Effect of exosomes on antioxidation in APAP- or H2O2-induced injury in hepatocytes. Liver stress/defense-related genes
expression in TAMH cells treated with or without exosomes concurrently in (A) 2 mM APAP or (B) 350 μM H2O2 for 24 hours. All the expressions
were determined by quantitative real-time PCR, normalized against GAPDH expression of the same sample and presented as fold-increase over
the controls. Bars represent mean ± SEM.
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explored such effect by using classic models of liver tox-
icity (that is, CCl4-induced hepatic injury in mouse). We
further considered the selectivity and the mechanism of
the anticipated protection by using in vitro models of
well-defined mechanisms of toxicity: APAP and H2O2. Ac-
cordingly, our experiments demonstrated that the MSC-
derived exosomes accelerated in vivo liver regeneration in
CCl4-injured mice. In addition, we found that exosomes
consistently caused increased cell viability after the injury
arising from both APAP- and H2O2.
In an in vivo study, CCl4 was used as a classic and well-
established model of acute liver injury. The administration
of MSC-derived exosomes was found to reverse CCl4-
induced injury in mice with active proliferation of hepato-
cytes, most clearly indicated with the expression of PCNA,
cyclin D1, and cyclin E. These proliferation effects were in
line with the in vitro findings in which exosomes were
able to sustain higher cell viability of hepatocytes after in-
juries cytotoxic doses of both APAP and H2O2. We quali-
fied the regenerative potential of these exosomes by
investigating the biochemical machinery behind the effect,beginning from the priming phase that triggers growth-
arrested injured cells to reenter cell cycle.
IL-6 [21] and TNF-α [22] are prominent priming fac-
tors in initiating liver regeneration on injury by commit-
ting cells to cell cycling. Yamada et al. [22] reported
defective DNA synthesis in TNFR-I-deficient mice after
partial hepatectomy, whereas IL-6 injection restored the
liver regeneration. Besides these, iNOS has also been
demonstrated to mediate the formation of nitric oxide
(NO) [23,24] and COX-2, which catalyzes the rate-
limiting step in the synthesis of prostaglandins (PGs)
that control the regenerative process. MIP-2 was also
found to enhance hepatocytes proliferation through up-
regulating nuclear translocation of STAT-3 during the
process of recovery from injury [25-27]. Our results
demonstrated the increase in expressions of all these
priming-phase factors after exosomes treatment along-
side improved cell viability. Despite the use of a mono-
culture system comprising exclusively hepatocytes, we
were able to pick up these cytokine perturbations, con-
sistent with other similar liver cell-line studies reported
in the literature [28,29].
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κB and IL-6-dependent pathway, which involves STAT3
transcription factor [30] in the G1 phase. In the current
investigation, Western blot demonstrated that injured
hepatocytes with exosomes treatment markedly in-
creased the expression of NF-κB and STAT3 transcrip-
tion factors. The IL-6/STAT3 pathway subsequently
innervates cell-cycle progression from G1 to S phase, as
shown in the upregulation of cyclin D1 and PCNA after
exosomes treatment. In line with the priming factors
and transcription factors, all these upregulated gene and
protein expressions collectively support a restoration
of overall cell viability, suggesting that the exosomes
therapy likely mediates the liver repair from acute liver
injury through induction of liver regeneration in the
hepatocytes.
In the process of characterizing the mode of action of
exosomes, we were aware of a possible differential re-
sponse to the type of cellular injury invoked by the toxi-
cants. Hence, two mechanistically distinct injury models
were investigated. APAP is a well-studied hepatotoxicant
that mediates the liver-injury pathway principally through
generation of its reactive metabolite, N-acetyl-p-benzoqui-
noneimine (NAPQI) and subsequent binding to hepatic
proteins [31], whereas H2O2 mediates liver injury solely
through the oxidative-stress pathway. However, a com-
mon effect observed in both injuries is the manifestation
of mitochondrial dysfunction, leading to apoptosis [32,33].
Because the exosomes demonstrated a protective or
injury-repair effect in both models, albeit to a different ex-
tent, a possible effect in mitigating oxidative stress was in-
vestigated. Previously, STAT3 was also shown to regulate
mitochondrial Bcl-xL and MnSOD expression in inhibiting
caspase 3 during apoptosis [18,20]. Our results demon-
strated that the Bcl-xL expression increased with higher
expression of STAT3 after the treatment of exosomes,
whereas caspase 3/7 expression was significantly de-
creased in the APAP-injury group treated with exosomes.
This suggests that exosomes were able to alleviate some
mitochondrial dysfunction as part of its plethora of pro-
tective mechanisms in the antiapoptosis pathway. How-
ever, exosomes did not demonstrate a role in regulating
antioxidative genes, and hence did not mitigate injury via
modulation of oxidative stress. These suggest that exo-
somes primarily assert antiapoptotic, proliferative, and
regenerative hepatic responses to liver damage.
Follow-up work would be necessary to determine
the hepatoprotective components within the exosomes.
Exosomes have been shown to contain biologically active
proteins, lipids, mRNA, and miRNA [34-36]. Lai et al.
profiled a total of 857 proteins in the exosomes by using
mass spectrometry and antibody array [37]. Here, few of
the prominent proteins that are potential components in-
volved in the liver-regeneration process were identified.Among them, IL6ST/gp130, TNFRSF1A/TNFR1, and
CXCL2/MIP-2 proteins were found to be associated with
the priming factors during liver regeneration. IL6ST plays
an important role in mediating the IL-6/STAT3 pathway,
which initiates the hepatocytes protection [38-40]. Like-
wise, CXCL2/MIP-2 enhances hepatocytes proliferation
through upregulating STAT-3 during the process of recov-
ery from injury [25-27]. These proteinaceous contents
could be released from the exosomes intrahepatically, trig-
gering the higher expressions of IL-6, TNF-α, and MIP-2
after treatment, as shown in our results.
Apart from the priming factors, HGF and hepatocyte
growth factor receptor (HGFR) proteins, which are among
the most potent stimulators of hepatocyte growth in liver
regeneration [41,42], can also be found in the exosomes.
These proteins might be working synergistically with the
priming factors in accelerating and promoting liver regen-
eration, leading to a restoration of homeostasis. However,
it remains to be determined whether miRNAs or other
mRNAs found in the exosomes may have any impact on
the proliferation effect of the hepatocytes.
Conclusion
In conclusion, exosomes treatment demonstrated liver
recovery after several toxicants-induced injuries. It is
mediating this effect, likely through maintaining the liver
homeostasis, that primarily includes inducing hepato-
cytes regeneration. This treatment may present a novel
adjunctive therapy in drug-induced liver toxicity, in lieu
of the limited availability of the conventional liver
transplants. Its attractiveness also lies largely on its
non-cell-based system, which reduces the risk of tissue
incompatibility, while using an abundant and reprodu-
cible supply. This work supports further investigation to
clarify the exact mechanism of action so that the intended
therapeutic effect can be translated and optimized.
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